If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Strong topline growth driven by solid performance across key brands.
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Subscribe To Our Newsletter & Stay Updated
